Installation of dominant-negative mutations in FAS and TGFβR2 via base editing in primary T cells
Molecular Therapy Oncology · 2025-12 · 33 (4) · 201063
DOI: 10.1016/j.omton.2025.201063 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Therapy Oncology, 2025-12. Verfasst von Bryce J Wick und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, University of Minnesota, Minneapolis, MN 55454, USA. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIAID NIH HHS, NCI NIH HHS, NIA NIH HHS.
Abstract (Originalsprache)
Adoptive cell transfer (ACT) of engineered T cells is effective against B cell malignancies but has faltered against solid tumors due to the immunosuppressive tumor microenvironment (TME). FAS ligand (FASL) and transforming growth factor β (TGF-β) are key mediators of T cell dysfunction in the TME and overexpressing dominant negative (dn) forms of their receptors in T cells increases anti-tumor efficacy in solid tumor models. However, an approach that directly targets the endogenous genes would be more amenable to multiplex editing and reduce competition with WT alleles. Here, we employ base editing (BE) in primary human T cells to install naturally occurring dominant negative FAS and TGFβR2 mutations. In vitro survival and proliferation assays demonstrate that BE T cells are resistant to pro-apoptotic and anti-proliferative effects of FAS and TGF-β signaling. Chimeric antigen receptor (CAR)-T cells with BE-installed dn TGFβR2 or dn FAS exhibit improvements in cytotoxicity, while dn TGFβR2 CAR T demonstrate increased persistence and reduced expression of phenotypic markers of exhaustion compared to controls. Moreover, BE-engineered dn CAR T outperform lentiviral-engineered cDNA over expression counterparts in several functional assays. Considering the efficiency of BE and its amenability for multiplex editing, our approach lends itself to engineering strategies necessary to overcome T cell dysfunction in solid tumors.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pediatrics, University of Minnesota, Minneapolis, MN 55454, USA.
- Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55455, USA.
- Center for Genome Engineering, University of Minnesota, Minneapolis, MN 55455, USA.
- Molecular and Cellular Biology Graduate Program, University of Washington, Seattle, WA 98195, USA.
- Human Biology Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.
Förderung
- NIAID NIH HHS
- NCI NIH HHS
- NIA NIH HHS
- NHLBI NIH HHS
- NIH HHS
- Randy Shaver Cancer Research and Community Fund
- MIB Agents
- National Institutes of Health
Zitieren
APA
Wick, B. J., Kluesner, M. G., Slipek, N. J., Skeate, J. G., Niemeyer, E. M., Webber, B. R., & Moriarity, B. S. (2025). Installation of dominant-negative mutations in FAS and TGFβR2 via base editing in primary T cells. Molecular Therapy Oncology, 33(4), 201063. https://doi.org/10.1016/j.omton.2025.201063
Vancouver
Wick BJ, Kluesner MG, Slipek NJ, Skeate JG, Niemeyer EM, Webber BR, et al. Installation of dominant-negative mutations in FAS and TGFβR2 via base editing in primary T cells. Molecular Therapy Oncology. 2025;33(4):201063. doi:10.1016/j.omton.2025.201063
BibTeX
@article{Wick2025,
author = {Wick, Bryce J and Kluesner, Mitchell G and Slipek, Nicholas J and Skeate, Joseph G and Niemeyer, Ethan M and Webber, Beau R and Moriarity, Branden S},
title = {Installation of dominant-negative mutations in FAS and TGFβR2 via base editing in primary T cells},
journal = {Molecular Therapy Oncology},
year = {2025},
volume = {33},
number = {4},
pages = {201063},
doi = {10.1016/j.omton.2025.201063}
}
EUVIMED